Refine
Has Fulltext
- yes (3)
Is part of the Bibliography
- yes (3)
Document Type
- Doctoral Thesis (3)
Language
- English (3)
Keywords
Institute
- Graduate School of Life Sciences (3) (remove)
Due to a usually late diagnosis, drug resistance and early metastases, pancreatic ductal adenocarcinoma (PDAC) is the seventh leading cause of global cancer deaths. Thus, there is an urgent need to develop new therapeutic concepts. Two different approaches have in recent years become the focus of intense research: (1) targeting cancer-associated metabolic rearrangements, and (2) targeting genetic vulnerabilities with combination therapy. Both concepts potentially have advantages such as increased efficacy, which decreases the likelihood of therapy-resistance, and reduced side effects, that are often associated with high concentrations of chemotherapeutic drugs. Autophagy is an evolutionary conserved signalling pathway that regulates cellular homeostasis. Regarding cancer, autophagy can either promote or suppress tumor growth. However, mouse models that allow genetic regulation of autophagy in established tumor tissue are not yet established. Therefore, we analysed new inducible shRNA mouse models targeting Atg5 or Atg7 with regard to functionality and toxicity. Both, shRNA Atg5- and shRNA Atg7-mediated knockdown anteceded functional autophagy impairment, and revealed unexpected profound phenotypic differences. Knockdown of Atg5 neither impaired the animal nor caused any grossly or microscopically detectable organ damage, whereas knockdown of Atg7 caused pancreatic destruction and eventually death. It is currently unclear whether mice died as a result of exocrine or endocrine collapse or due to a combination of both. The presented mouse models are highly potent RNAi mice that allow widespread and regulable inhibition of autophagy upon administration of doxycycline and provide a valuable and versatile toolbox for future autophagy and cancer research. In PDAC, argininosuccinate synthase 1 (ASS1) deficiency has been associated with higher recurrence rates, shorter disease-free survival, and shorter overall survival. During cancer development, rate-limiting enzymes of de novo arginine synthesis, like ASS1 or OTC, are downregulated via epigenetic silencing of their respective promotor. Known as ‘arginine auxotrophy‘, loss of these essential enzymes results in dependence on extracellular arginine. Based on this assumption, sensitivity of various cell lines to arginine deprivation was reported. However, the underlying mechanism is still unclear and the anti-tumor effects of the monotherapy are not sufficient to completely abrogate cancer cells. Therefore, the effects of arginine deprivation via rhArgI-PEG5000 were investigated in murine and human PDAC cells. In this study, we highlighted that arginine deprivation induced profound alterations such as autophagosome accumulation, induction of senescence and the ISR in pancreatic cancer cells. These alterations are potential genetic vulnerabilities that can be targeted by additional means to induce tumor cell death.
Inefficient vascularisation of solid tumours leads to the formation of oxygen and nutrient gradients. In order to mimic this specific feature of the tumour microenvironment, a multicellular tumour spheroid (SPH) culture system was used. These experiments were implemented in p53 isogenic colon cancer cell lines (HCT116 p53 +/+ and HCT116 p53-/-) since Tp53 has important regulatory functions in tumour metabolism. First, the characteristics of the cells cultured as monolayers and as spheroids were investigated by using RNA sequencing and metabolomics to compare gene expression and metabolic features of cells grown in different conditions. This analysis showed that certain features of gene expression found in tumours are also present in spheroids but not in monolayer cultures, including reduced proliferation and induction of hypoxia related genes. Moreover, comparison between the different genotypes revealed that the expression of genes involved in cholesterol homeostasis is induced in p53 deficient cells compared to p53 wild type cells and this difference was only detected in spheroids and tumour samples but not in monolayer cultures. In addition, it was established that loss of p53 leads to the induction of enzymes of the mevalonate pathway via activation of the transcription factor SREBP2, resulting in a metabolic rewiring that supports the generation of ubiquinone (coenzyme Q10). An adequate supply of ubiquinone was essential to support mitochondrial electron transport and pyrimidine biosynthesis in p53 deficient cancer cells under conditions of metabolic stress. Moreover, inhibition of the mevalonate pathway using statins selectively induced oxidative stress and apoptosis in p53 deficient colon cancer cells exposed to oxygen and nutrient deprivation. This was caused by ubiquinone being required for electron transfer by dihydroorotate dehydrogenase, an essential enzyme of the pyrimidine nucleotide biosynthesis pathway. Supplementation with exogenous nucleosides relieved the demand for electron transfer and restored viability of p53 deficient cancer cells under metabolic stress. Moreover, the mevalonate pathway was also essential for the synthesis of ubiquinone for nucleotide biosynthesis to support growth of intestinal tumour organoids. Together, these findings highlight the importance of the mevalonate pathway in cancer cells and provide molecular evidence for an enhanced sensitivity towards the inhibition of mitochondrial electron transfer in tumour-like metabolic environments.
p97 uses the energy of ATP hydrolysis to unfold and thereby segregate proteins. It is involved in various cellular processes such as proteasomal degradation, DNA damage repair, autophagy, and endo-lysosomal trafficking. The specificity for these processes is controlled by more than 30 regulatory cofactors.
Interactions of p97 with cofactors and target proteins are known to be highly dynamic and transient. To identify new interaction partners and to uncover novel cellular functions of p97, the interactome of endogenous p97 was determined by using in cellulo crosslinking followed by immunoprecipitation and mass spectrometry. Myoferlin (MYOF) was identified as a novel interactor of p97 and the interaction was validated in reciprocal immunoprecipitation experiments for different cell lines.
The ferlin family member MYOF is a tail-anchored membrane protein containing multiple C2 domains. MYOF is involved in various membrane repair and trafficking processes such as the endocytic recycling of cell surface receptors. The MYOF interactome was determined by mass spectrometry. Among others, the p97 cofactor PLAA, CD71 and Rab14 were identified as common interactors of p97 and MYOF. Immunoprecipitation experiments with PLAA KO cells revealed that the interaction between MYOF and p97 depends on PLAA. Immunofluorescence microscopy showed a co-localization of MYOF with Rab14 and Rab11, which are both involved in endocytic recycling pathways. Furthermore, immunofluoroscence experiments revealed that MYOF and the p97 cofactor PLAA are localized to Rab14- and Rab5-positive endosomal compartments.
Using p97 inhibitors and p97 trapping mutants, the presence of p97 at MYOF-positive and Rab14-positive structures could be demonstrated. Consistent with this finding, the endocytic recycling of transferrin was delayed upon inhibition of p97. Taken together, this work identified MYOF as a novel interactor of p97 and suggests a role for p97 in the recycling of endocytic cargo.